Enanta Pharmaceuticals | ENTA - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Amgen USD 6.89B 415M 2025-12
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 264.03M 7.56M 2025-12
AstraZeneca USD 12.61B 225M 2026-03
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.82B 169.5M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Immunic 0 0 2025-03
Incyte USD 1.17B 217.51M 2026-03
Insmed USD 256.46M 38.78M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
J&J USD 17.24B 642M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
Ligand Pharmaceuticals USD 48.45M 8.22M 2026-03
Merck USD 10.85B 2.57B 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.07B 184M 2026-03
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 11.04B 1.24B 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03